Table 2.
The key data of all studies targeting the dopamine receptor
| Year | First author | Tracer (Target) | Method | TS patients | Healthy controls | Scores | Drug free |
|---|---|---|---|---|---|---|---|
| 1994 | Turjanski | RACLOPRIDE (D2/3) | PET | 5 | 9 | no | 3 month |
| 2000 | Müller-Vahl | IBZM (D2) | SPECT | 10 | 7 | STSS 3,4 (6) | 12 month |
| 2002 | Singer | RACLOPRIDE (D2/3) | PET | 7 | 5 | YGTSS 38 (100) | 6 month |
| 2008 | Hwang | I-IBZM (D2) | SPECT | 11 | 15 | MRVRS 11,7 (20) | 3 month |
| 2008 | Wong | RACLOPRIDE (D2/3) | PET | 11 | 7 | YGTSS 50,27 (100) | 6 month |
| 2013 | Denys | RACLOPRIDE (D2/3) | PET | 12 | 12 | YGTTS 17 (50) | 6 month |
| 2015 | Black | RACLOPRIDE (D2/3) | PET | 5 | 5 | YGTSS 27,8 (100) | Drug naive |
| 2015 | Abi-Jaoude | RACLOPRIDE (D2/3) | PET | 11 | 11 | YGTTS 19,9 (50) | 3 month |
| SUM | 72 | 71 |
Method: positron emission tomography (PET), single-photon emission computed tomography (SPECT). Scores: Yale Global Tic Severity Scale (YGTSS); Shapiro Tourette Syndrome Severity Scale (Shapiro STSS); Modified Rush Videotape Rating Scale (MRVRS). Drug free: Drug free interval before scan